Company Description
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain.
Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain.
It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia.
The company is headquartered in Palo Alto, California.
Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Country | United States |
| IPO Date | Mar 5, 2021 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Jaisim Shah |
Contact Details
Address: 960 San Antonio Road Palo Alto, California United States | |
| Website | https://www.scilexholding.com |
Stock Details
| Ticker Symbol | SCLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001820190 |
| CUSIP Number | 80880W106 |
| ISIN Number | US80880W1062 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaisim Shah | President, Chief Executive Officer & Director |
| Dr. Suketu D. Desai Ph.D. | Chief Technology Officer & Senior Vice President |
| Stephen Ma | Senior Vice President, Chief Financial Officer & Corporate Secretary |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President & Chief Medical Officer |
| Dr. Henry H. Ji Ph.D. | Executive Chairman |
| Gigi DeGuzman | Senior Executive Director & Chief of Staff |
| Mike Ciaffi | National Sales Director |
| Steven F. Lincoln J.D. | General Counsel & Chief Compliance Officer |
| Sumant Rajendran | Executive Director of Marketing |
| Suresh K. Khemani | Senior Vice President & Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 03, 2025 | 424B3 | Filing |
| Jan 03, 2025 | 424B3 | Filing |
| Jan 03, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 4 | Filing |
| Dec 17, 2024 | 4 | Filing |
| Dec 17, 2024 | 4 | Filing |
| Dec 17, 2024 | 4 | Filing |